An FDA advisory panel voted this week to add six peptides to the drug compounding list, including compounds like kisspeptin and TB-500. The panel rejected emideltide. Shares of HIMS climbed overnight following the committee's endorsement of four peptides. Bachem shares held steady after the vote. A recent study indicated peptides may help treat antibiotic-resistant bacteria. Meanwhile, Robert F. Kennedy Jr. pushed for easier access to controversial peptides, calling for loosened oversight. The vote reflects a broader shift in how policymakers view specialty peptide therapies, which have drawn increasing interest from consumers seeking alternatives to standard drugs. Scientists say peptide treatments could alter approaches to stubborn infections, though concerns about consistency persist. The committee's endorsement of six peptides clears a path for more widespread prescribing, even as critics warn of limited evidence. Sector observers note that peptide-focused companies may see heightened investor attention following the panel's decision. The rejection of emideltide, meanwhile, underscores the FDA's cautious stance on particular peptide candidates.